<DOC>
	<DOC>NCT02607904</DOC>
	<brief_summary>This trial consists of 2 parts: a double-blinded phase and an open-label extension phase. The open-label extension phase only will be described in this record. All participants will receive the same dose of GWP42003-P. However, investigators may subsequently decrease or increase the participant's dose until the optimal dose is found.</brief_summary>
	<brief_title>An Open-label Extension Trial to Investigate Possible Drug-drug Interactions Between Stiripentol or Valproate and Cannabidiol in Patients With Epilepsy</brief_title>
	<detailed_description />
	<mesh_term>Epilepsy</mesh_term>
	<mesh_term>Stiripentol</mesh_term>
	<mesh_term>Valproic Acid</mesh_term>
	<criteria>Note: Participants who enroll in France or Sweden must be aged 1855 years. Key Participant must have a documented magnetic resonance imaging/computerized tomography of the brain that ruled out a progressive neurologic condition. Key Participant has clinically significant unstable medical conditions other than epilepsy. Participant has a history of symptoms related to a drop in blood pressure due to postural changes (e.g., dizziness, lightheadedness, blurred vision, palpitations, weakness, syncope). Participant has any history of suicidal behavior or any suicidal ideation of type 4 or 5 on the CSSRS in the last month. Participant is currently using felbamate and has been taking it for less than 12 months prior to screening visit of the blinded phase of the trial. Participant is currently using or has in the past used recreational or medicinal cannabis, or synthetic cannabinoidbased medications (including SativexÂ®) within the 3 months prior to trial entry. Participant has any known or suspected history of any drug abuse or addiction. Participant is unwilling to abstain from recreational or medicinal cannabis, or synthetic cannabinoidbased medications (including Sativex) for the duration for the trial. Participant has any known or suspected hypersensitivity to cannabinoids or any of the excipients of the Investigational Medicinal Product (IMP), e.g., sesame oil.</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Cannabidiol</keyword>
	<keyword>GWP42003-P</keyword>
	<keyword>Epidiolex</keyword>
	<keyword>Stiripentol</keyword>
	<keyword>Valproate</keyword>
</DOC>